159 related articles for article (PubMed ID: 29541402)
1. Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype.
Derakhshandeh R; Sanadhya S; Lee Han K; Chen H; Goloubeva O; Webb TJ; Younis RH
Oncotarget; 2018 Feb; 9(13):11126-11144. PubMed ID: 29541402
[TBL] [Abstract][Full Text] [Related]
2. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
Younis RH; Han KL; Webb TJ
J Immunol; 2016 Feb; 196(3):1419-29. PubMed ID: 26740106
[TBL] [Abstract][Full Text] [Related]
3. Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile.
Younis RH; Ghita I; Elnaggar M; Chaisuparat R; Theofilou VI; Dyalram D; Ord RA; Davila E; Tallon LJ; Papadimitriou JC; Webb TJ; Bentzen SM; Lubek JE
Front Immunol; 2021; 12():596646. PubMed ID: 33776991
[TBL] [Abstract][Full Text] [Related]
4. Cytokine profiling in plasma distinguishes the histological inflammatory subtype of head and neck squamous cell carcinoma and a novel regulatory role of osteopontin.
Ghita I; Piperi E; Atamas SP; Bentzen SM; Ord RA; Dyalram D; Lubek JE; Younis RH
Front Oral Health; 2022; 3():993638. PubMed ID: 36338570
[TBL] [Abstract][Full Text] [Related]
5. Semaphorin 4D promotes bone invasion in head and neck squamous cell carcinoma.
Takada H; Ibaragi S; Eguchi T; Okui T; Obata K; Masui M; Morisawa A; Takabatake K; Kawai H; Yoshioka N; Hassan NMM; Shimo T; Hu GF; Nagatsuka H; Sasaki A
Int J Oncol; 2017 Aug; 51(2):625-632. PubMed ID: 28656278
[TBL] [Abstract][Full Text] [Related]
6. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.
Basile JR; Castilho RM; Williams VP; Gutkind JS
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9017-22. PubMed ID: 16754882
[TBL] [Abstract][Full Text] [Related]
7. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
8. Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma cell proliferation, migration and invasion.
Cao J; Zhang C; Chen T; Tian R; Sun S; Yu X; Xiao C; Wang G; Liu Y; Fu M; Li W
J Dermatol Sci; 2015 Aug; 79(2):127-36. PubMed ID: 26051877
[TBL] [Abstract][Full Text] [Related]
9. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
10. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
11. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
Kato S; Kubota K; Shimamura T; Shinohara Y; Kobayashi N; Watanabe S; Yoneda M; Inamori M; Nakamura F; Ishiguro H; Nakaigawa N; Nagashima Y; Taguri M; Kubota Y; Goshima Y; Morita S; Endo I; Maeda S; Nakajima A; Nakagama H
Cancer Sci; 2011 Nov; 102(11):2029-37. PubMed ID: 21812859
[TBL] [Abstract][Full Text] [Related]
12. The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer.
Ding X; Qiu L; Zhang L; Xi J; Li D; Huang X; Zhao Y; Wang X; Sun Q
Onco Targets Ther; 2016; 9():1189-204. PubMed ID: 27022279
[TBL] [Abstract][Full Text] [Related]
13. Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.
Yoshida Y; Ogata A; Kang S; Ebina K; Shi K; Nojima S; Kimura T; Ito D; Morimoto K; Nishide M; Hosokawa T; Hirano T; Shima Y; Narazaki M; Tsuboi H; Saeki Y; Tomita T; Tanaka T; Kumanogoh A
Arthritis Rheumatol; 2015 Jun; 67(6):1481-90. PubMed ID: 25707877
[TBL] [Abstract][Full Text] [Related]
14. The role of Sema4D/CD100 as a therapeutic target for tumor microenvironments and for autoimmune, neuroimmune and bone diseases.
Wu M; Li J; Gao Q; Ye F
Expert Opin Ther Targets; 2016 Jul; 20(7):885-901. PubMed ID: 26732941
[TBL] [Abstract][Full Text] [Related]
15. Semaphorin 4D induces vaginal epithelial cell apoptosis to control mouse postnatal vaginal tissue remodeling.
Ito T; Bai T; Tanaka T; Yoshida K; Ueyama T; Miyajima M; Negishi T; Kawasaki T; Takamatsu H; Kikutani H; Kumanogoh A; Yukawa K
Mol Med Rep; 2015 Feb; 11(2):829-36. PubMed ID: 25351707
[TBL] [Abstract][Full Text] [Related]
16. Semaphorin 4D and hypoxia-inducible factor-1α overexpression is related to prognosis in colorectal carcinoma.
Wang JS; Jing CQ; Shan KS; Chen YZ; Guo XB; Cao ZX; Mu LJ; Peng LP; Zhou ML; Li LP
World J Gastroenterol; 2015 Feb; 21(7):2191-8. PubMed ID: 25717256
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors.
Trellakis S; Farjah H; Bruderek K; Dumitru CA; Hoffmann TK; Lang S; Brandau S
Int J Immunopathol Pharmacol; 2011; 24(3):683-93. PubMed ID: 21978700
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Semaphorin-3A and Semaphorin-4D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia.
Parsa S; Sharifzadeh S; Monabati A; Seyyedi N; Ranjbaran R; Baghbani MR; Nemati M; Jafarzadeh A
Int J Hematol Oncol Stem Cell Res; 2019 Jan; 13(1):25-34. PubMed ID: 31205625
[No Abstract] [Full Text] [Related]
19. Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents.
Zuazo-Gaztelu I; Pàez-Ribes M; Carrasco P; Martín L; Soler A; Martínez-Lozano M; Pons R; Llena J; Palomero L; Graupera M; Casanovas O
Cancer Res; 2019 Oct; 79(20):5328-5341. PubMed ID: 31239269
[TBL] [Abstract][Full Text] [Related]
20. Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Movila A; Mawardi H; Nishimura K; Kiyama T; Egashira K; Kim JY; Villa A; Sasaki H; Woo SB; Kawai T
Biochem Biophys Res Commun; 2016 Nov; 480(1):42-47. PubMed ID: 27720716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
